In a phase I trial, Yang et al. investigated the safety of intracoronary delivery of Ad-HGF (replication-deficient HAd-5 expressing the pro-angiogenic growth factor human hepatocyte growth factor; 5 × 109, 1 × 1010, and 2 × 1010 PFU) in patients with severe CAD [151]. Here, HGF is linked to coronary artery disorder.